PBMWW
Psyence Biomedical Ltd - Warrants (25/01/2029) (PBMWW)
NASDAQ • $0.03+6.50%
- Symbol
- PBMWW
- Exchange
- NASDAQ
- Sector
- Industry
- Price
- $0.03
- Daily Change
- +6.50%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $0.03
- 52W Low
- $0.03
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.79
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaborat…
Company websiteResearch PBMWW on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.